DA Davidson & Co reiterates its Buy rating for USANA Health Sciences USNA following the company's Q4 2011 earnings results. Its price target on the company remains $46.
In the report, DA Davidson & Co writes, "USANA Health Sciences reported Q4 operating EPS of $0.87, up 15.3% from $0.75 last year. Net sales of $146 million increased 6.1% year-over-year, in line with our expectation. USANA's shares remain very attractive and our price target remains $46."
USANA Health Sciences are currently trading at $36.57, up 2.09% from yesterday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in